Ignite Creation Date:
2025-12-18 @ 6:13 AM
Ignite Modification Date:
2025-12-18 @ 6:13 AM
Study NCT ID:
NCT00786552
Status:
None
Last Update Posted:
2011-01-20 00:00:00
First Post:
2008-11-05 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer
Sponsor:
None
Organization:
Study Overview
Official Title:
Phase 2 Trial of Pemetrexed (Alimta™) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer
Status:
None
Status Verified Date:
2011-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Panthera
Brief Summary:
The aims of this trial are to evaluate the efficacy and tolerability of pemetrexed + paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: